Αρχική World News Scientists find cells in centre of tumours are most likely to spread

Scientists find cells in centre of tumours are most likely to spread

Kidney cancer under the microscope

Scientists have discovered that cells from different parts of kidney tumours behave differently and those in the centre are the most dangerous – in a “critical” step towards understanding how to target cancer spread.

Cancer can move from one part of the body to another to form secondary tumours. Known as metastasis, this spreading makes the disease much harder to treat.

Now a new study by researchers from the Francis Crick Institute, Royal Marsden, UCL and Cruces University Hospital, funded in part by Cancer Research UK and published in Nature Ecology and Evolution, has unearthed fresh information about cancer migration that could lead to new treatments.

“These findings are a critical foundation for considering how we target or even prevent distinct populations of cells that pose the biggest threat.” – Dr Samra Turajlic, chief investigator of TRACERx Renal

Central cells more likely to spread

scientists led by the Litchfield lab at UCL and the Turajlic, Swanton, and Bates labs at the Crick analysed 756 kidney cancer biopsy samples from different regions within tumours, taken from the TRACERx Renal study.

They discovered cells at the centre of tumours have a less stable genome – which includes all the genetic material of an organism – and are more likely to spread to other areas of the body. In comparison, cells at the edge of the tumour lower rates of growth and genetic damage.

Samra Turajlic, chief investigator of TRACERx Renal, explained that cancer spread is one of the “biggest barriers to improving survival rates”.

“In the context of the TRACERx Renal Study we previously resolved the genetic make up of different tumour areas, but until now, there has been no understanding of how these differences relate spatially,” she said. “The most critical question is the part of the tumour from which cancer cells break away and migrate making cancer incurable.”

A ‘critical foundation’ for tackling aggressive cancer

The new discoveries have exposed the tumour’s centre as the key to locating its most aggressive cells. This, study authors say, has highlighted the need to develop treatments that target the unique environmental conditions found within the tumour core in order to eliminate them.

Kevin Litchfield, paper author and group leader at the UCL Cancer Institute, said: “Cancer cells in the central zone of the tumour face harsh environmental conditions, as there’s a lack of blood supply and oxygen.”

He pointed out this also means they are more likely to successfully evolve into cells that can spread widely and take hold in distant organs.

Samra Turajlic added: “Our observations shed light on the sort of environmental conditions that would foster emergence of aggressive behaviour. These findings are a critical foundation for considering how we target or even prevent distinct populations of cells that pose the biggest threat.”

Delving even deeper

The scientists also studied how genetically different populations of cancer cells grow within a tumour. By using a unique map building tool to reconstruct the growth of tumour cells, they were able to make another surprising discovery.

Although most tumours follow a pattern where populations of cells grow in the local area, such as a plant growing up and outwards, they found two cases with a “jumping” pattern. It appeared as though these cells had taken hold in a new part of the tumour by jumping over other populations of tumour cells.

The researchers now plan to reconstruct ‘3D tumour maps’ which will allow them to see the spatial patterns within tumours even more clearly.

The study was also funded by the Royal Marsden Renal Unit, Biomedical Research Centre at the Royal Marsden and Institute of Cancer Research, Rosetrees Trust, the National Institute for Health Research (NIHR) and the EU Framework Programme for Research and Innovation H2020.


Zhao, Y et al. (2021) Selection of metastasis competent subclones in the tumour interior. Nature Ecology and Evolution. DOI: 10.1038/s41559-021-01456-6

More on this topic



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...